CLOs on the Move

Xenon Pharmateuticals

www.xenon-pharma.com

 
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Nathaniel Adams
Senior Director, Legal Affairs Profile
Andrea DiFabio
Chief Legal Officer and Corporate Secretary Profile

Similar Companies

CommunityCare of Oklahoma Health Insurance Plans

CommunityCare, one of the largest health care companies in Oklahoma, is locally owned and operated by Saint Francis Health System and St. John Health System in Tulsa. CommunityCare offers a wide variety of group and individual products, including HMO, HRA, POS and PPO plans, Medicare Advantage plans, Medicare supplement plans, an employee assistance program and a workers` compensation plan. CommunityCare is proud to be Oklahoma`s best choice for health care.

Mattson Jack Group

Mattson Jack Group is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Saint Louis, MO. To find more information about Mattson Jack Group, please visit www.mattsonjack.com

Jack Nathan Health

At Jack Nathan Health, we are committed to improving access to public health care to over 1.1 million patients per-year by delivering consistent, quality care in state-of-the-art medical and dental clinics in Walmart stores across Canada. Jack Nathan Health is proud to partner with Walmart Canada to deliver quality health care services and convenience to its customers. Walmart currently operates over 390 stores and serves more than 1 million customers each day across Canada. They are the third largest employer in Canada with more than 90,000 associates and offer a full range of groceries, general merchandise and specialty services - including Medical & Dental Clinics - under one roof.

Eleven Biotherapeutics

"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."

Epic Laser

Epic Laser is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.